Takeda
Manufacturing · Japan · 10K+ Employees
View Company Info for Free
Overview
Headquarters
1-1 Nihonbashi-honcho Chuo-ku, Tokyo, To...Phone Number
+81 332782111Website
www.takeda.comRevenue
$29 BillionStock Symbol
TAKIndustry
About Takeda
Takeda Org Chart
Is Takeda your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when Takeda launches new products
Congratulate Masked Content for being promoted to Masked Content at Takeda
Funding: Get notified immidiatlly once Takeda has new funding data
Takeda, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Takeda is spiking on competitors!
Earning: See what the market has to say on Takeda recently announced quarterly report
Check if Takeda has recently received funding, and reach out quickly before it becomes old news!
Click to see if Takeda had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Takeda is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Takeda is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Takeda.
Takeda Tech Stack
A closer look at the technologies used by Takeda
Most Recent Scoops
Takeda News & Media
Takeda Announces Planned Retirement of President of Research & Development Andy Plump
Takeda has announced that Andy Plump, M.D., Ph.D., President Research & Development (and member of the Board of Directors), will retire from Takeda, effective June 2027.Can Keros Therapeutics (KROS)’s $20M Takeda Pharmaceutical Company Limited (TAK) Milestone Unlock a Billion-Dollar Opportunity?
On July 30, Keros Therapeutics, Inc. (NASDAQ:KROS) triggered a $20 million development milestone payment from its global partner Takeda Pharmaceutical Company Limited (NYSE:TAK). The payout followed the first patient dosed in the Phase 3 ELRiSE MDS clinical trial, evaluating elritercept against epoetin alfa for anemia caused by low-to-intermediate-risk myelodysplastic syndromes. Under their January 2025 global […]Takeda Pharmaceutical Company Limited (TAK) Q1 2026 Earnings Call Transcript
Takeda (TAK) Q1 FY2026 earnings call: core revenue -0.5% CER, pipeline and launch updatesKeros Receives $20M Milestone as Elritercept Phase 3 Trial Enrolls First Patient
Keros receives $20M milestone as elritercept Phase 3 trial enrolls first patient in MDS study with demanding transfusion independence endpoint.
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Takeda
Founded in 1781, Takeda Pharmaceutical Company engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such... Read More